Sosei Heptares actively participates in the next European Training Network ONCORNET 2.0
By Chris de Graaf | Jun 5, 2019
The EU has awarded 4 million Euros for ITN research programme ONCORNET2.0, which aims to understand and target two oncogenic G protein-coupled receptors (GPCRs) highly expressed in multiple tumors. The consortium will develop new strategies for chemokine receptor modulation and investigate their effects on oncogenic responses, to yield key new knowledge and potential leads for drug development.
Next EU Training Network ONCORNET2.0 on oncogenic GPCR networks
The EU has granted 4 M euro to Martine Smit and Jacqueline van Muijlwijk (Medicinal Chemistry, AIMMS, Faculty of Science, Vrije Universiteit Amsterdam) and colleagues from academia and SMEs from the Netherlands, France, Germany, Spain, UK and Switzerland.
ONCORNET2.0 builds on the success of ONCORNET (Oncogenic GPCR Network of Excellence and Training), a first-in-kind ITN in GPCR drug discovery that has successfully delivered scientific advance and training to talented early stage researchers (ESRs) (www.oncornet.eu).
GPCR proteins in tumors
ONCORNET2.0 will incorporate recent scientific and technological breakthroughs (e.g. cryo-EM, CRISPR-Cas, advanced microscopy) to understand and target two oncogenic G protein-coupled receptors (GPCRs); the chemokine receptors CXCR4 and ACKR3 (CXCR7). These are highly expressed in multiple tumours but their role in cancer progression remains poorly understood.
We will develop new strategies for CXCR4/ACKR3 modulation and investigate their effects on oncogenic responses, to yield key new knowledge and potential leads for drug development.
Leading research in Europe
ONCORNET2.0 will bring together the leading GPCR research groups in Europe and will educate the next generation of young researchers (15 PhD students) by a multi-disciplinary training.
This programme integrates both research (e.g. drug discovery, proteomics, imaging) and transferable (e.g. entrepreneurship, academic writing, media training) skill sets through blended learning. This will ensure that the ESRs can effectively operate in today’s drug discovery programs and will increase European competitiveness in the field of drug discovery.